1. McConville MJ, De Souza D, Saunders E, et al. Living in a phagolysosome; metabolism of Leishmania amastigotes. Trends in parasitology 2007; 23(8): 368-75. 2. Mougneau E, Bihl F, Glaichenhaus N. Cell biology and immunology of Leishmania. Immunol Rev 2011; 240: 286-96. 3. Ardehali S, Rezaei HR, Nadim A. Angal Lishmania & Liashmaniouzha. Tehran: Iran University Press, 1373, 3-9. (Persian) 4. COX FE. History of human parasitology. Clin Microbiol Rev 2002; 15(4): 595-612. 5. Tajbakhsh H. History of veterinary medicine and medicine of Iran. Tehran: University of Tehran Press, 1371, 497. (Persian) 6. Polack E.J. Persien. Das Land und seine Bewohner: Ethnographische Schilderungen. Tehran: Kharazmi, 1368, 486-473. (Persian) 7. Floor W. Public Health In Qajar Iran. Canada: Mage Publishers, 2003, 39-40. 8. Ardehali S, Rezaei HR, Nadim A. Leishmania and Leishmaniasis parasites. In: Sadeghi R, editors. 2th ed. Tehran: Iran University Press, 1373, 12-200. (Persian) 9. Nadim A, Seyedi RM. A brief review of the epidemiology of various types of leishmaniasis in Iran. Acta Medica Iranica 1971; 4(8): 99-106. 10. Nadim A, Faghih MA. The epidemiology of cutaneous leishmaniasis in Isfahan province of Iran. I. the reservoir. II. the human disease. Trans R Soc Trop Med Hyg 1968; 62: 534-42. 11. Nadim A, Seyedi-Rashti MA, Mesghali A. Epidemiology of cutaneous leishmaniasis in Turkemen Sahara, Iran. J Trop Med Hyg 1968; 71(9): 238-9. 12. Javadian E, Nadim A, Tahvildare-Bidruni G, et al. Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan Part V: Report on a focus of zoonotic cutaneous leishmaniasis in Esferayen. Bull Soc Pathol Exot Filiales 1976; 69(2): 140-3. 13. Nadim A, Seyedi-Rashti MA, Faghih M. Epidemiology of cutaneous leishmaniasis in Iran. B. Khorasan. Part III. Human infection. Bull Soc Path ExotFiliales 1969; 62: 702-0. 14. Javadian E, Mesghali A. Studies on cutaneous leishmaniasis in Khuzestan, Iran. Part I. The leptomonad infection of sandflies. Bull Soc Pathol Exot Filiales 1974; 67(5): 513-6. 15. Moaddeb A, Gettner S, Ardehali S. Studies on the causative agent of cutaneous leishmaniasis in Shiraz-Iran. Iran J Med Sci 1993; 18: 28-33. 16. Sharifi I, Aflatoonian MR, Fekri AR, et al. A Comprehensive Review of Cutaneous Leishmaniasis in Kerman Province, Southeastern Iran-Narrative Review Article. Iran J Public Health 2015; 44(3): 299-307. 17. Nadim A, Javadian E, Seyedi Rashti M.A. Leishmaniasis epidemic in Iran, Angal Lishmania & Liashmaniuz-ha. Iran: Tehran,1992, 176-208. (Persian) 18. Aflatoonian MR, Sharifi I, Aflatoonian B. A Review of Impact of Bam Earthquake on Cutaneous Leishmaniasis and Status: Epidemic of Old Foci, Emergence of New Foci and Changes in Features of the Disease. J Arthropod-Borne Dis 2016; 10(3): 271–280. 19. Mahmoudzadeh-Niknam H, Ajdary S, Riazirad F, et al. Molecular epidemiology of cutaneous leishmaniasis and heterogeneity of Leishmania major strains in Iran. Trop Med Int Health 2012; 17(11): 1335-44. 20. Shirzadi, MR. A Leishmaniasis (salaak) Care Guide in Iran. Iran: Tehran, 2012, 18-21. (Persian) 21. Yaghoobi-Ershadi MR, Akhavan AA, Zahraei-Ramazani AR, et al. Field trial for the control of zoonotic cutaneous leishmaniosis in Badrood, Iran. Ann Saudi Med 2000; 20 (5-6): 386-9. 22. Yaghoobi-Ershadi MR, Moosa-Kazemi SH, Zahraei-Ramazani AR, et al. Evaluation of deltamethrin-impregnated bed nets and curtains for control of zoonotic cutaneous leishmaniasis in a hyperendemic area of Iran. Bull Soc Pathol Exot 2006; 99(1): 43-8. 23. Veysi A, Vatandoost H, Yaghoobi-Ershadi M, et al. Comparative study on the effectiveness of Coumavec® and zinc phosphide in controlling zoonotic cutaneous leishmaniasis in a hyperendemic focus in central Iran. Journal of arthropod-borne diseases 2012; 6(1): 18-27. 24. Nadim A, Javadian E, Tahvildar-Bidruni G, et al. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 1983; 76(4): 377-83. 25. Nadim A, Javadian E, Tahvildar-Bidruni G, et al. Control of zoonotic cutaneous leishmaniasis by mass leishmanization in hyperendemic area of Isfahan. MJIRI 1988; 2(2): 113-4. 26. Nicole C, Manceaux L. Recherches sur le bouton d'Orient: cultures, reproduction expérimentale, immunisation. Annales de Institute Pasteur 1910; 24: 673-720. 27. Berberian DA. Vaccination and Immunity against Oriental Sore. Trans R Soc Trop Med Hyg 1939; 33(1): 87-91. 28. Senekji HA, Beattie CP. Artificial Infection and Immunization of Man with Cultures of Leishmania tropica. Trans R Soc Trop Med Hyg 1941; 34(6): 415-419. 29. Kellina OI. Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the USSR. Bull Soc Pathol Exot Filiales 1981; 74(3): 306-18. 30. Sergiev VP. Control and prophylaxis of cutaneous leishmaniasis in the middle Asia republics of the former USSR. Bulletin de la Société française de parasitologie 1992; 10(2): 183-7. 31. Gafurov IM. Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan. Med Parazitol (Mosk) 1999; (1): 58-9. 32. Nadim A. Research On Control Strategies for the Leist-Ttaniases. In: Walton B, Wijeyarertne PM, Modabber F, editors. Leishmanization in the Islamic Republic of Iran. International Development Research Center IDRC-MR 184e, Ottawa, 1988, 336-69. 33. Modabber F. First generation leishmaniasis vaccines in clinical development: moving, but what next. Curr Opin Investig Drugs 2000; 2: 35-9. 34. Modabber F. Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 2010; 36 Suppl 1: S58-61. 35. Hashemi-Fesharaki R, Ale-Agha S, Habibi GR, et al. Production of inactivated wet rural Leishmania major. Iran J Med Sci 1998; 23: 74-80. 36. Alimohammadian MH, Hakimi H, Nikseresht M. The P Reparation And Evaluation Of Reference Leishmanin From Leishmania Major For Use In Man For Diagnos Tic And Experimental Purposes. MJIRI 1993; 15: 7(1): 23-8. 37. Mohebali M, Javadian EH, Hashemi-Fesharaki R, et al. Trial of a non-living crude vaccine against zoonotic cutaneous leishmaniasis. MJIRI 1995; 8(4): 211-15. 38. Farrar GH, Robinson A, Wiblin CN. Vaccine Protocols. New York: Humana Press, 1996, 251-68. 39. Dowlati Y, Ehsasi S, Shidani B, et al. Stepwise safety trial of a killed Leishmania vaccine in Iran. Clinics in Dermatology 1996; 14(5): 497-502. 40. Bahar K, Dowlati Y, Shidani B, et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 1996; 14(5): 489-95. 41. Sharifi I, Fekri AR, Aflatonian MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351(9115): 1540-3. 42. Momeni AZ, Jalayer T, Emamjomeh M, et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17(5): 466-72. 43. Khalil EAG, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356(9241):1565-9. 44. Alimohammadian MH, Khamesipour A, Darabi H, et al. The role of BCG in human responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine againstleishmaniasis. Vaccine 2002; 21(3-4): 174-80. 45. Kamil AA, Khalil EAG, Musa AM, et al. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003; 97(3): 365-8. 46. Modabber F. Development of vaccine against leishmaniasis. 6th International Congress of Immunology and Allergy [Brochure]; 2002 May; Iran University of Medical Sciences, Iran. Tehran: Iranian Society for Immunology and Allergy, 2002, 65. 47. Smrkovski LL, Larson CL. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun 1977; 16(1): 249-57.
|